#aacr2019 search results
Dr. Susan Domchek: Questionnaire to surgeons re surg mgmt of variants of unknown significance & deleterious mutations in #BRCA: 25% of high-volume & 50% of low-vol surgeons said they’d manage ppl w/ VUS in same way as ppl w/deleterious. (Wrong answer 😳). #AACR19 #AACR2019
Chairing & presenting a session on "Convergence of Artificial Intelligence, Big Data, and Prediction in Cancer" (right now!). Can’t make it? Here’s my slides (+ disclosures here: goo.gl/6kfq2E ) #AACR2019
There were noticeable increases in certain RNAs in the exosomes that came from patients with cancer compared to those without. #AACR19 #AACR2019 bit.ly/2K6vXH5
AACR 信号峠で15分オーバーしましたが なんとかゴールしましたああああああああああ お疲れ様でしたあああああああああ #AACR #AACR2019 #安曇野アルプスセンチュリーライド
Morning #aacr2019! Come this morning to our @polyethnic1000 poster, section 32: “Advancing cancer genomics by studying ethnically diverse, underserved patient populations in New York”. Also accessible at nygenome.org/bioinformatics…
We've released a @PacBio Iso-Seq melanoma cancer dataset: github.com/PacificBioscie… that was presented at #AACR2019 this year. Make good use of it!
NRG1 fusions are found across cancer types, including otherwise driver-negative NSCLC and pancreas cancer. Exciting new target! #AACR2019 @alexdrilon @RymaBenayed @MLadanyi
58% of NSCLC patients have better survival with #immunotherapy drug, nivolumab. ms.spr.ly/6012TGHAm #AACR2019
Members of the @SU2C-@lustgartenfdn Pancreatic Cancer Dream Team are describing the results from the first clinical trial of a PDAC vaccine with attenuated mesothelin-expressing L. monocytogenes w/wo nivolumab at #AACR2019 #AACR19 standuptocancer.org/research/resea…
According to « tweeters » from colleagues attending to AACR (thank you for sharing), this is the impressive panorama in oncogenic NSCLC. Best sequence, genomic profile at PD, drugs available, brain activity are some future challenges #AACR2019
58% of #NSCLC patients have better survival with immunotherapy drug, nivolumab. ms.spr.ly/6011TGHAb #AACR2019
AACRのエイド食で一番記憶に残ったのは気温37℃の中で提供された熱々の豚汁でまさに凶器だった。旨いけど。#AACR #AACR2019 #安曇野アルプスセンチュリーライド
本日はありがとうございました！ 明日のAACRではプチエイドをやります！ 例年通り無料で麦茶を用意、 自転車のトラブルに空気入れや工具もあります。 有料でエイド食＆りんごジュースとぶどうジュースを冷やしてお待ちしておりますので、よろしくお願い致します！ #北ヤマト園 #AACR2019 #緑のAACR
#AACR2019 の後半動画うpしましたー！ 引き続き長野の絶景風景をご覧ください😊 後半は坂が登場！果たして初の120km完走なるか・・・！？ ロードバイクで絶景グルメライド！緑のアルプスあづみのセンチュリーライド120km【後編】 youtu.be/UAv5jB-8hs0 #ロードバイク #緑のAACR
Final session for me at #AACR2019 #AACR19 with Angelika Amon and Tyler Jacks from the @kochinstitute speaking about genomic and transcriptional instability in cancer
Domchek: Reassuring news. About 8% of VUS have been reclassified. Of these, 91% ⬇️ to non-deleterious & 9% ⬆️ to pathogenic bit.ly/2WBC9IF #AACR19 #AACR2019 #BRCA #GeneticTesting #oncology
One big question the authors have: Are these exosomes functional? #AACR19 #AACR2019 bit.ly/2FQ5t7p
58% of #NSCLC patients have better survival with immunotherapy drug, nivolumab. ms.spr.ly/6015TGXhV #AACR2019
Qualigen Therapeutics presents promising data on QN-247 for Triple Negative Breast Cancer at #AACR2019. More Info: pryzm.ozmosi.com/product/14190 $XBI $IBB $XPH $PPH
You are not just funding research but also supporting consortia like @CaPTC7, which are training African cancer investigators. Paraphrasing what @NCIDrDougLowy said during #AACR2019, we are indeed drinking from the well dug and getting warmed by the fire build by...(well) you.🙏
This week our parent company @Evotec are at #AACR2019 in Boston. Meet SVP Head of Oncology, Mark Whittaker to discuss your requirements. Get in touch to arrange a meeting | [email protected] @AACR #Targets19 #researchneverstops
This week @Evotec are at #AACR2019 in Boston. Meet SVP Head of Oncology, Mark Whittaker to discuss your requirements. Get in touch to arrange a meeting | [email protected] @AACR #Targets19 #researchneverstops
This week @Evotec are at #AACR2019 in Boston. Meet SVP Head of Oncology, Mark Whittaker to discuss your requirements. Get in touch to arrange a meeting | [email protected] @AACR #Targets19 #researchneverstops
This week we are at #AACR2019 in Boston. Meet SVP Head of Oncology, Mark Whittaker to discuss your requirements. Get in touch to arrange a meeting | [email protected] @AACR #Targets19 #researchneverstops
Tomorrow our parent company @Evotec will be at #AACR2019 in Boston. Meet SVP Head of Oncology, Mark Whittaker to discuss your requirements. Get in touch to arrange a meeting | [email protected] @AACR #researchneverstops
Tomorrow @Evotec will be at #AACR2019 in Boston. Meet SVP Head of Oncology, Mark Whittaker to discuss your requirements. Get in touch to arrange a meeting | [email protected] @AACR #researchneverstops
Tomorrow @Evotec will be at #AACR2019 in Boston. Meet SVP Head of Oncology, Mark Whittaker to discuss your requirements. Get in touch to arrange a meeting | [email protected] @AACR #researchneverstops
Tomorrow we will be at #AACR2019 in Boston. Meet SVP Head of Oncology, Mark Whittaker to discuss your requirements. Get in touch to arrange a meeting | [email protected] @AACR #researchneverstops
$ZYME ZW25+ Chemo Combo in HER2 expressing GEA (median 3 of prior anti-cancer regimens): 63 % ORR and 27 % AE ≥ 3 . For comparison: $AZN T-Dxd: 43 % ORR and 47 % AE ≥ 3. #AACR2019
Next week @Evotec will be at #AACR2019 in Boston. Meet EVP Head of Business Development and US Operations, Ryan Brady and SVP Head of Oncology, Mark Whittaker to discuss your requirements. Get in touch to arrange a meeting | [email protected] @AACR #researchneverstops
Next week our parent company @Evotec will be at #AACR2019 in Boston. Meet EVP Head of Business Development and US Operations, Ryan Brady and SVP Head of Oncology, Mark Whittaker to discuss your needs. Get in touch to arrange a meeting | [email protected] @AACR #researchneverstops
Next week @Evotec will be at #AACR2019 in Boston. Meet EVP Head of Business Development and US Operations, Ryan Brady and SVP Head of Oncology, Mark Whittaker to discuss your requirements. Get in touch to arrange a meeting | [email protected] @AACR #researchneverstops
Next week we will be at #AACR2019 in Boston. Meet EVP Head of Business Development and US Operations, Ryan Brady and SVP Head of Oncology, Mark Whittaker to discuss your requirements. Get in touch to arrange a meeting | [email protected] @AACR #researchneverstops
Jan Oldenburg, Medical Oncologist : What do we need to improve cancer patient treatment selection ? well... #AACR2019
Chairing & presenting a session on "Convergence of Artificial Intelligence, Big Data, and Prediction in Cancer" (right now!). Can’t make it? Here’s my slides (+ disclosures here: goo.gl/6kfq2E ) #AACR2019
Congratulations to Dr. Andrew Chan @MGHCancerCenter winner of this years @AACR Waun Ki Hong prize. Celebrating here with the Hong family and friends. Ki would be delighted by this awardee who is making so much progress in cancer prevention! @SU2C @MDAndersonNews #AACR2019
Dr. Maeve Mullooly (RCSI) presenting her breast cancer research at the #AACR2019 - well done! @IrishCancerSoc @RCSI_Irl
58% of NSCLC patients have better survival with #immunotherapy drug, nivolumab. ms.spr.ly/6012TGHAm #AACR2019
According to « tweeters » from colleagues attending to AACR (thank you for sharing), this is the impressive panorama in oncogenic NSCLC. Best sequence, genomic profile at PD, drugs available, brain activity are some future challenges #AACR2019
Antibody drug conjugates in cancer: what is the direction? Check out #AACR2019 Interactome web tool by @Sagebio and @VHIO cancer.sagebionetworks.org/adc.html
58% of #NSCLC patients have better survival with immunotherapy drug, nivolumab. ms.spr.ly/6011TGHAb #AACR2019
#AACR2019 の後半動画うpしましたー！ 引き続き長野の絶景風景をご覧ください😊 後半は坂が登場！果たして初の120km完走なるか・・・！？ ロードバイクで絶景グルメライド！緑のアルプスあづみのセンチュリーライド120km【後編】 youtu.be/UAv5jB-8hs0 #ロードバイク #緑のAACR
Final session for me at #AACR2019 #AACR19 with Angelika Amon and Tyler Jacks from the @kochinstitute speaking about genomic and transcriptional instability in cancer
A presidential evening @AACR #AACR2019 at the reception to honor Elizabeth Jaffee@HopkinsKimmel Ran into past ASCO President @drbrucejohnson @ASCO and @DrFadloKhuri from @AUB_Lebanon Also Jeff Allen @CancerResrch. Lots of great new data in Atlanta @SU2Cscience
Domchek: Reassuring news. About 8% of VUS have been reclassified. Of these, 91% ⬇️ to non-deleterious & 9% ⬆️ to pathogenic bit.ly/2WBC9IF #AACR19 #AACR2019 #BRCA #GeneticTesting #oncology
58% of #NSCLC patients have better survival with immunotherapy drug, nivolumab. ms.spr.ly/6015TGXhV #AACR2019
Surgery to remove primary breast tumor improves survival in Stage IV breast cancer. ms.spr.ly/6014T10Ho #BCSM #AACR2019
Something went wrong.
Something went wrong.
United States Trends
- 1. Tim Cook N/A
- 2. John Ternus N/A
- 3. Happy 420 N/A
- 4. SNAP N/A
- 5. DPOY N/A
- 6. #thespreadsheet N/A
- 7. Steve Jobs N/A
- 8. Lori Chavez-DeRemer N/A
- 9. The Onion N/A
- 10. Infowars N/A
- 11. No FISA N/A
- 12. Bill Simmons N/A
- 13. $AAPL N/A
- 14. Executive Chairman N/A
- 15. Labor Secretary N/A
- 16. Victor Wembanyama N/A
- 17. Defensive Player of the Year N/A
- 18. Slade Cecconi N/A
- 19. Edwin Díaz N/A
- 20. Solo Ball N/A